224 related articles for article (PubMed ID: 27835867)
1. Keratin 13 expression reprograms bone and brain metastases of human prostate cancer cells.
Li Q; Yin L; Jones LW; Chu GC; Wu JB; Huang JM; Li Q; You S; Kim J; Lu YT; Mrdenovic S; Wang R; Freeman MR; Garraway I; Lewis MS; Chung LW; Zhau HE
Oncotarget; 2016 Dec; 7(51):84645-84657. PubMed ID: 27835867
[TBL] [Abstract][Full Text] [Related]
2. Keratin 13 Is Enriched in Prostate Tubule-Initiating Cells and May Identify Primary Prostate Tumors that Metastasize to the Bone.
Liu S; Cadaneanu RM; Zhang B; Huo L; Lai K; Li X; Galet C; Grogan TR; Elashoff D; Freedland SJ; Rettig M; Aronson WJ; Knudsen BS; Lewis MS; Garraway IP
PLoS One; 2016; 11(10):e0163232. PubMed ID: 27711225
[TBL] [Abstract][Full Text] [Related]
3. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
4. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
5. KRT13 promotes stemness and drives metastasis in breast cancer through a plakoglobin/c-Myc signaling pathway.
Yin L; Li Q; Mrdenovic S; Chu GC; Wu BJ; Bu H; Duan P; Kim J; You S; Lewis MS; Liang G; Wang R; Zhau HE; Chung LWK
Breast Cancer Res; 2022 Jan; 24(1):7. PubMed ID: 35078507
[TBL] [Abstract][Full Text] [Related]
6. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.
Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW
Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054
[TBL] [Abstract][Full Text] [Related]
7. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
8. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.
Zheng Y; Basel D; Chow SO; Fong-Yee C; Kim S; Buttgereit F; Dunstan CR; Zhou H; Seibel MJ
Clin Exp Metastasis; 2014 Dec; 31(8):921-33. PubMed ID: 25223386
[TBL] [Abstract][Full Text] [Related]
9. Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.
Zheng Y; Chow SO; Boernert K; Basel D; Mikuscheva A; Kim S; Fong-Yee C; Trivedi T; Buttgereit F; Sutherland RL; Dunstan CR; Zhou H; Seibel MJ
J Bone Miner Res; 2014 Sep; 29(9):1938-49. PubMed ID: 24676805
[TBL] [Abstract][Full Text] [Related]
10. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases.
Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E
BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568
[TBL] [Abstract][Full Text] [Related]
11. Effect of PI3K/Akt Signaling Pathway on the Process of Prostate Cancer Metastasis to Bone.
Zhu W; Hu X; Xu J; Cheng Y; Shao Y; Peng Y
Cell Biochem Biophys; 2015 May; 72(1):171-7. PubMed ID: 27040945
[TBL] [Abstract][Full Text] [Related]
12. Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.
Odero-Marah VA; Wang R; Chu G; Zayzafoon M; Xu J; Shi C; Marshall FF; Zhau HE; Chung LW
Cell Res; 2008 Aug; 18(8):858-70. PubMed ID: 18645583
[TBL] [Abstract][Full Text] [Related]
13. Bone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.
Nandana S; Tripathi M; Duan P; Chu CY; Mishra R; Liu C; Jin R; Yamashita H; Zayzafoon M; Bhowmick NA; Zhau HE; Matusik RJ; Chung LW
Cancer Res; 2017 Mar; 77(6):1331-1344. PubMed ID: 28108510
[TBL] [Abstract][Full Text] [Related]
14. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
[TBL] [Abstract][Full Text] [Related]
16. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of nuclear factor-kappa B ligand (RANKL) stimulates bone-associated tumors through functional RANK expressed on bone-associated cancer cells?
Mori K; Ando K; Heymann D; Rédini F
Histol Histopathol; 2009 Feb; 24(2):235-42. PubMed ID: 19085839
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
19. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
20. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease.
Hellawell GO; Turner GD; Davies DR; Poulsom R; Brewster SF; Macaulay VM
Cancer Res; 2002 May; 62(10):2942-50. PubMed ID: 12019176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
